Global, regional and national burden of endocrine, metabolic, blood and immune disorders 1990-2019: a systematic analysis of the Global Burden of Disease study 2019.
blood and immune disorders
death
disability-adjusted-life-years
endocrine
metabolic
years-lived-with-disability
years-of-life-lost
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
12
2022
accepted:
03
04
2023
medline:
26
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Endocrine, metabolic, blood and immune disorders (EMBID) is a vital public health problem globally, but the study on its burden and global trends was scarce. We aimed to evaluate the global burden of disease and trends in EMBID from 1990 to 2019. We extracted the data of EMBID-related on death cases, Age-standardized death rates (ASDRs), disability-adjusted life-years (DALYs), Age-standardized DALY rates, years of life lost (YLLs), Age-standardized YLL rates, years lived with disability (YLDs) and Age-standardized YLD rates between 1990 and 2019 from the Global Burden of Disease 2019, by sex, age, and year at the global and geographical region levels. The Annual rate of change was directly extracted from Global Health Data Exchange (GHDx) and we also calculated the age-related age-standardized rate (ASR) to quantify trends in EMBID-related deaths, DALYs, YLLs and YLDs. Globally, the EMBID-related ASDRs showed an increasing trend, whereas the DALYs ASR, YLLs ASR and YLDs ASR were decreased between 1990 to 2019. Furthermore, High-income North America and Southern Sub-Saharan Africa had the highest both ASDRs and DALYs ASR, and Southern Sub-Saharan Africa and Caribbean had the highest both YLDs ASR and YLLs ASR in 2019. Males had a higher EMBID-related ASDRs than females, but the DALYs ASR in females were higher than males. The burden of EMBID was higher in older-aged compared to other age groups, especially in developed regions. Although EMBID-related ASRs for DALYs-, YLLs- and YLDs declined at the global level from 1990 to 2019, but the ASDRs was increasing. This implied high healthcare costs and more burden of ASDRs due to EMBID in the future. Therefore, there was an urgent need to adopt geographic targets, age-specific targets, prevention strategies and treatments for EMBID to reduce negative health outcomes globally.
Sections du résumé
Background
Endocrine, metabolic, blood and immune disorders (EMBID) is a vital public health problem globally, but the study on its burden and global trends was scarce. We aimed to evaluate the global burden of disease and trends in EMBID from 1990 to 2019.
Methods
We extracted the data of EMBID-related on death cases, Age-standardized death rates (ASDRs), disability-adjusted life-years (DALYs), Age-standardized DALY rates, years of life lost (YLLs), Age-standardized YLL rates, years lived with disability (YLDs) and Age-standardized YLD rates between 1990 and 2019 from the Global Burden of Disease 2019, by sex, age, and year at the global and geographical region levels. The Annual rate of change was directly extracted from Global Health Data Exchange (GHDx) and we also calculated the age-related age-standardized rate (ASR) to quantify trends in EMBID-related deaths, DALYs, YLLs and YLDs.
Result
Globally, the EMBID-related ASDRs showed an increasing trend, whereas the DALYs ASR, YLLs ASR and YLDs ASR were decreased between 1990 to 2019. Furthermore, High-income North America and Southern Sub-Saharan Africa had the highest both ASDRs and DALYs ASR, and Southern Sub-Saharan Africa and Caribbean had the highest both YLDs ASR and YLLs ASR in 2019. Males had a higher EMBID-related ASDRs than females, but the DALYs ASR in females were higher than males. The burden of EMBID was higher in older-aged compared to other age groups, especially in developed regions.
Conclusion
Although EMBID-related ASRs for DALYs-, YLLs- and YLDs declined at the global level from 1990 to 2019, but the ASDRs was increasing. This implied high healthcare costs and more burden of ASDRs due to EMBID in the future. Therefore, there was an urgent need to adopt geographic targets, age-specific targets, prevention strategies and treatments for EMBID to reduce negative health outcomes globally.
Identifiants
pubmed: 37223046
doi: 10.3389/fendo.2023.1101627
pmc: PMC10200867
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1101627Informations de copyright
Copyright © 2023 Wu, Lin, Huang, Shen and Shan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA Netw Open. 2020 Jul 1;3(7):e209993
pubmed: 32644139
Int J Behav Nutr Phys Act. 2020 Sep 3;17(1):111
pubmed: 32883294
Int J Environ Res Public Health. 2019 Aug 04;16(15):
pubmed: 31382672
Nature. 1996 Sep 19;383(6597):224
pubmed: 8805695
J Intern Med. 2017 Feb;281(2):106-122
pubmed: 27597529
Ann Intern Med. 2015 Jan 20;162(2):123-32
pubmed: 25599350
Lancet. 2018 Sep 22;392(10152):1072-1088
pubmed: 30264707
Health Policy. 2022 Jan;126(1):69-73
pubmed: 32113665
Curr Opin Rheumatol. 2005 Jan;17(1):64-9
pubmed: 15604907
J Clin Endocrinol Metab. 2009 Jun;94(6):1853-78
pubmed: 19494161
Bioessays. 2013 Feb;35(2):93-9
pubmed: 23281153
BMJ. 2019 Apr 5;365:l1631
pubmed: 30952650
Arch Dis Child. 2020 Nov;105(11):1035-1040
pubmed: 32198161
Thyroid. 2002 Oct;12(10):925-9
pubmed: 12487775
Cell Metab. 2016 Jun 14;23(6):1022-1033
pubmed: 27304504
Reprod Sci. 2010 Jun;17(6):511-31
pubmed: 20460551
Int J Environ Res Public Health. 2021 Nov 28;18(23):
pubmed: 34886270
Alcohol Res. 2017;38(2):255-276
pubmed: 28988577
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
J Gerontol A Biol Sci Med Sci. 2018 Jan 16;73(2):175-184
pubmed: 28977345
Front Public Health. 2016 Jan 25;4:3
pubmed: 26835445
Drug Alcohol Rev. 2021 Mar;40(3):402-419
pubmed: 33629786
BMJ. 2019 Nov 27;367:l6326
pubmed: 31776110
J Gerontol A Biol Sci Med Sci. 2018 Jan 16;73(2):141-149
pubmed: 28525535
JAMA. 2018 Mar 13;319(10):1024-1039
pubmed: 29536101
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
Postgrad Med. 1989 Apr;85(5):271-8, 281-3
pubmed: 2648373
Rheumatology (Oxford). 2013 Apr;52(4):599-608
pubmed: 23315787
Demography. 2010 Aug;47(3):555-78
pubmed: 20879677
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
Lancet Psychiatry. 2018 Dec;5(12):987-1012
pubmed: 30392731
Mol Biol Rep. 2022 May;49(5):3911-3918
pubmed: 35229241
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326